Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.

@article{Smalley2006MultipleSP,
  title={Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.},
  author={Keiran Sm Smalley and Nikolas K. Haass and Patricia A. Brafford and Mercedes I Lioni and Keith T. Flaherty and Meenhard Herlyn},
  journal={Molecular cancer therapeutics},
  year={2006},
  volume={5 5},
  pages={1136-44}
}
Although >66% of melanomas harbor activating mutations in BRAF and exhibit constitutive activity in the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase signaling pathway, it is unclear how effective MEK inhibition will be as a sole therapeutic strategy for melanoma. We investigated the anticancer activity of MEK inhibition in a panel of cell lines derived from radial growth phase (WM35) and vertical growth phase (WM793… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 202 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

BRAF mutation predicts sensitivity to MEK inhibition

Nature • 2006
View 5 Excerpts
Highly Influenced

Multiple Molecular Cancer Therapeutics 1143 Mol Cancer Ther 2006;5(5)

R Sears, F Nuckolls, +3 authors JR. Nevins
May 2006 on April • 2006
View 1 Excerpt

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…